Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Development of type 1 conventional dendritic cells (cDC1s) underlies the capacity to generate antiviral and antitumor immune responses. Here, we identify the basis for cDC1 development from its earliest progenitors, determining the hierarchy of several required transcription factors and uncovering a series of mandatory cis interactions between constituent enhancers within the superenhancer. We produced in vivo mutations of two C/EBPα binding sites that comprise the +56-kilobase (kb) enhancer that markedly reduced IRF8 expression in all myeloid progenitors and impaired cDC1 development. These sites did not bind RUNX1 or RUNX3, and C/EBPα expression was instead regulated by their action at the +37-kb enhancer, placing RUNX factors upstream of in regulating . Last, we demonstrate that cis interactions between the +56-kb enhancer and the previously reported +41- and +32-kb enhancers are mandatory in the sequential progression of these stage-specific constituent elements.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/sciimmunol.adt5899 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.
Hepatology
September 2025
Department of Pathology, Department of Molecular Biology, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA.
Background And Aims: So far, there is no effective mechanism-based therapeutic agent tailored for liver tumors. Immune checkpoint inhibitors (ICIs) have demonstrated limited efficacy in liver cancer, often associated with severe adverse effects. Although poly-inosinic:cytidylic acid (polyIC) has shown an adjuvant effect when combined with anti-PD-L1 antibody (αPD-L1) in treating liver tumors in animal models, its systemic toxicity limits its clinical utility.
View Article and Find Full Text PDFMucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
J Virol
August 2025
Department of Immunology, International Cancer Center, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Unlabelled: A combination of vaccination strategies will potentially be required for effective control of the virus pandemic. We report that mice intranasally immunized with commercial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subunit vaccines enriched with the human thymic stromal lymphopoietin (TSLP) variant, long-form TSLP (lfTSLP), but not the short-isoform TSLP (sfTSLP), induced robust antigen-specific systemic and mucosal antibody production. The adjuvant-enhancing activity of lfTSLP in mice requires functional TSLP receptor signals in migratory type 1 conventional dendritic cells (cDC1s).
View Article and Find Full Text PDFTractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells.
J Vis Exp
August 2025
Molecular Medicine and Gene Therapy, Science for Life Laboratory, Lund Stem Cell Centre, Lund University; Wallenberg Centre for Molecular Medicine, Lund University; Centre for Neuroscience and Cell Biology, University of Coimbra;
The efficacy of cancer immunotherapy relies on the recruitment and activation of cytotoxic T cell responses against solid tumors by type 1 conventional dendritic cells (cDC1s). However, the generation of cDC1s for cancer immunotherapy faces significant limitations, including poor cell yield, functional heterogeneity, and susceptibility to immunosuppression in the tumor microenvironment (TME). We recently developed an immunotherapy modality based on in vivo reprogramming of cancer cells into immunogenic cDC1-like cells, which enabled cancer cells to present tumor antigens as cDC1s and elicited polyclonal cytotoxic T cell responses and durable systemic anti-tumor immunity.
View Article and Find Full Text PDFCheckpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4 T cells in MDS.
Blood Neoplasia
August 2025
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
A growing body of literature suggests that the efficacy of DNA hypomethylating agents are mediated via activation of antitumor immune mechanisms. Based upon this hypothesis, early phase trials combining immune checkpoint inhibitors (ICIs) with azacitidine in patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) were undertaken, but clinical and immunologic efficacy have proven disappointing. In these studies, the lack of antigen specificity made systematic assessment of the anti-MDS immune response challenging.
View Article and Find Full Text PDFDesign and Characterization of an Anti-Clec9a Antibody Armed with CpG Oligonucleotides To Enable Targeted Delivery of Adjuvant to Cross-Presenting Dendritic Cells.
ACS Chem Biol
August 2025
Bristol-Myers Squibb Research & Development, 700 Bay Road, Redwood City, California 94063, USA.
C-type lectin receptor, Clec9a, is a highly specific receptor expressed on cross-presenting conventional dendritic cells (cDC1). This receptor specificity for this rare population of dendritic cells (DCs), combined with their inherent ability to internalize and localize to the endocytic compartment, presents a unique opportunity for targeted delivery of innate immune agonists. By leveraging an anti-Clec9a antibody, we can specifically deliver these agonists to cross-presenting cDCs, thereby enhancing the cross-priming and expansion of tumor-specific cytotoxic T lymphocytes (CTLs).
View Article and Find Full Text PDF